Dr. Rick Patt
Dr. Patt is co-founder and principal in RadMD. He has a broad prior experience in medical imaging: this includes research and development of contrast agents: design and manage site and central reviews and trained reviewers for over 300 oncology trials; and has expertise in cardiovascular device, infectious disease, and pulmonary fibrosis trials. He has performed blinded reads and adjudications in a variety of trial types. He has held positions as both an academic and private practice radiologist.
After his fellowship at Georgetown University and the National Institutes of Health (NIH), he served as Chief of Body MRI, then Director of MRI, at Georgetown University Medical Center, where he was both an investigator and blinded reader in numerous pharmaceutical and medical device clinical trials.
He subsequently joined Berlex Labs as Associate Director, followed by Director of Medical Imaging Clinical Development. where he managed an experienced team in all phases of clinical development of radiological contrast agents.
Dr. Patt also served as Medical Director for HealthHelp, a radiology management services organization. He founded Foresight Consulting, working with pharmaceutical and medical device companies on the utilization of medical imaging into clinical development programs.
He has numerous publications, has served on an NCI Advisory Panel, is a reviewer for major radiology journals, and has been an invited lecturer across the US and Europe on the use of medical imaging in clinical trials.
Dr. Kohkan Shamsi
Dr. Shamsi, MD, PhD, co-founder and principal of RadMD is a radiologist with 25+ years of clinical development experience for drugs and devices.
Before founding RadMD, he worked as research physician at Schering AG in Berlin, Germany and as Head of Medical Development and clinical operations at Berlex and Bayer and was CEO of US operations of ECRON ACUNOVA, a global clinical CRO. He has conceptualized, coordinated, and executed >100 multi-center, international (Europe, the USA, South America, Asia and Australia) clinical trials (phase I – phase IV) in the areas of oncology, cardiology, neurology and MRI and CT contrast agents and radiopharmaceuticals.
He has contributed towards development of guidelines for clinical development of contrast agents for the FDA and EMA, and the FDA draft imaging guidance for use of imaging in oncology trials. He has authored a book and chapters and published more than 90 full publications and abstracts in indexed journals. He is also part of industry initiative for standardization of imaging in clinical trials.